ArticleEnzyme research2011
Therapeutic Implications of Targeting AKT Signaling in Melanoma.
Article in Enzyme research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Physiological functions of calcium signaling via Orai1 in cancer.The journal of physiological sciences : JPS · 2023Review
- Rhabdoid melanoma in a harpy eagle (Veterinary and animal science · 2021Article
- Costunolide suppresses melanoma growth via the AKT/mTOR pathwayAmerican journal of cancer research · 2021Article
- AKT1Molecular cancer research : MCR · 2019Article
- Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.Bioscience reports · 2018Review
- Nanoliposomal delivery of cytosolic phospholipase ANanomedicine : nanotechnology, biology, and medicine · 2018Article
- Short-term heat stress altered metabolism and insulin signaling in skeletal muscle.Journal of animal science · 2018Article
- Overproduction of Sch9 leads to its aggregation and cell elongation in Saccharomyces cerevisiae.PloS one · 2018Article
- Transient receptor potential cation 3 channel regulates melanoma proliferation and migration.The journal of physiological sciences : JPS · 2017Article
- Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Article
- AKT1 Activation Promotes Development of Melanoma Metastases.Cell reports · 2015Article
- Identification of genes associated with melanoma metastasis.The Kaohsiung journal of medical sciences · 2015Article
- A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo.Scientific reports · 2015Article
- Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis.Molecular and cellular biology · 2015Article
- Subcutaneous adipocytes promote melanoma cell growth by activating the Akt signaling pathway: role of palmitic acid.The Journal of biological chemistry · 2014Article
- Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.BMC cancer · 2014Article
- Targeting multiple key signaling pathways in melanoma using leelamine.Molecular cancer therapeutics · 2014Article
- Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy.American journal of cancer research · 2012Article
- Chemoprevention of melanoma.Advances in pharmacology (San Diego, Calif.) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Identification of key enzymes regulating melanoma progression and drug resistance has the potential to lead to the development of novel, more effective targeted agents for inhibiting this deadly form of skin cancer. The Akt3, also known as protein kinase B gamma, pathway enzymes regulate diverse cellular processes including proliferation, survival, and invasion thereby promoting the development of melanoma. Accumulating preclinical evidence demonstrates that therapeutic agents targeting these kinases alone or in combination with other pathway members could be effective for the long-term treatment of advanced-stage disease. However, currently, no selective and effective therapeutic agent targeting these kinases has been identified for clinical use. This paper provides an overview of the key enzymes of the PI3K pathway with emphasis placed on Akt3 and the negative regulator of this kinase called PTEN (phosphatase and tensin homolog deleted on chromosome 10). Mechanisms regulating these enzymes, their substrates and therapeutic implications of targeting these proteins to treat melanoma are also discussed. Finally, key issues that remain to be answered and future directions for interested researchers pertaining to this signaling cascade are highlighted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.